BCTX BriaCell Therapeutics Corp.

FDA Catalyst Company
5.04
+0.57  (+13%)
Previous Close 4.47
Open 4.61
52 Week Low 2.82
52 Week High 12.47
Market Cap $77,007,551
Shares 15,279,276
Float 15,279,276
Enterprise Value $22,428,450
Volume 275,254
Av. Daily Volume 985,448
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/14/2022

Latest News

    • U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell's lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer.
    • Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients.
    • BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase I/IIa study, now with Fast Track designation.

    PHILADELPHIA and VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the U.S. Food and Drug Administration (FDA…

    View Full Article
    • Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy.
    • Bria-OTS™ will be used to treat patients with advanced breast cancer, providing patients with readily available personalized treatment.

    PHILADELPHIA and VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, presented the development details of its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, summarized in a poster session held at the American Association for Cancer Research (AACR) Annual Meeting…

    View Full Article
    • Bria-OTS™ would build on BriaCell's existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™ formulation based on HLA-type.
    • BriaCell and National Cancer Institute collaborating on Bria-OTS™, BriaCell's off-the-shelf personalized immunotherapy, as a treatment for cancer. 
    • BriaCell to present Bria-OTS™ approach at the American Association for Cancer Research (AACR) Annual Meeting 2022.

    PHILADELPHIA and VANCOUVER, British Columbia, April 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its novel…

    View Full Article
  1. PHILADELPHIA and VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recruited two additional clinical sites for screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat. The additional clinical sites include the following: 1) Atlantic Health System, Morristown, New Jersey, and 2) Tranquil Clinical Research, Webster, Texas.

    BriaCell's clinical sites…

    View Full Article
  2. PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that it has appointed leading immunologist, Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board.

    Dr. Kharazi co-invented Bria-IMT™, BriaCell's lead clinical candidate, in collaboration with Dr. Charles L. Wiseman, BriaCell's Founder and Principal Research Advisor. Dr. Kharazi currently serves as Chief Technology Officer at Stemedica Cell Technologies, Inc. His experience includes roles as Chief Scientist of the Immunotherapy laboratory…

    View Full Article
View All BriaCell Therapeutics Corp. News